Dr. Reddy's Recalls Zenatane Capsules Due to Dissolution Failure
Dr. Reddy's Laboratories is recalling Zenatane (isotretinoin) capsules because they failed to meet dissolution specifications. The recall covers 4,404 cartons distributed nationwide.
The agency’s classification
FDA (Drugs): Class III
Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 1/5 (Low).
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which by definition is unlikely to cause adverse health consequences, fitting the 'Low' severity criteria for documentation or minor specification issues.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling Zenatane (isotretinoin) capsules, 10 mg, packaged in 30-count cartons. The recall involves 4,404 cartons of the medication, which was distributed nationwide in the United States. The specific lot affected is KB60197, with an expiration date of 2/18.
The recall was initiated because the product failed to meet dissolution specifications, specifically showing low dissolution results at the S3 stage. Dissolution is a critical quality attribute that ensures the medication breaks down properly in the body to be absorbed effectively.
Consumers who have this specific lot of Zenatane should stop using it and contact their healthcare provider or pharmacist for guidance. The FDA has classified this recall as Class III, indicating that the violation of the product's labeling or manufacturing specifications is not likely to cause adverse health consequences.
The recalled product
- Product
- ZENATANE (ISOTRETINOIN)
- Brand
- ZENATANE
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 4,404
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # KB60197
- Exp 2/18
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 4 recalled by Dr. Reddy's Laboratories, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same brand · ZENATANE
- ModerateDr. Reddy's Recalls Zenatane Isotretinoin Capsules for Dissolution Failures
FDA (Drugs) · 2017-06-14
- ModerateDr. Reddy's Recalls Zenatane Capsules for Low Dissolution
FDA (Drugs) · 2017-06-14
- ModerateDr. Reddy's Recalls Zenatane Isotretinoin Capsules for Dissolution Failure
FDA (Drugs) · 2017-06-14
- ModerateDr. Reddy's Recalls Zenatane Isotretinoin Capsules for Dissolution Failures
FDA (Drugs) · 2017-06-14
- ModerateDr. Reddy's Recalls Zenatane Capsules for Dissolution Failure
FDA (Drugs) · 2017-03-08
Same manufacturer · Dr. Reddy's Laboratories, Inc.
See all →- ModerateVarenicline tablets recalled after an assay value fell below specification
FDA (Drugs) · 2025-12-17
- Moderate
- HighOmeprazole capsule bottle contained a foreign divalproex sodium tablet
FDA (Drugs) · 2025-07-23
- SevereLevetiracetam Injection Label Mismatch Nationwide Recall
FDA (Drugs) · 2025-04-23
- ModerateFDA Recalls JAVYGTOR Tablets Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-12-18
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paroxetine Hydrochloride Extended-Release Tablets for Dissolution Failure
FDA (Drugs) · 2026-10-07
- ModerateAjanta Pharma Recalls Ranolazine Tablets for Dissolution Failure
FDA (Drugs) · 2026-10-07
- ModerateMylan Recalls Mycophenolate Mofetil Injection Due to Dissolution Failures
FDA (Drugs) · 2026-09-09
- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
Similar recalls
- ModerateDr. Reddy's Recalls Zenatane Isotretinoin Capsules for Dissolution Failures
FDA (Drugs) · 2017-06-14
- ModerateDr. Reddy's Recalls Zenatane Capsules for Low Dissolution
FDA (Drugs) · 2017-06-14
- ModerateDr. Reddy's Recalls Zenatane Isotretinoin Capsules for Dissolution Failure
FDA (Drugs) · 2017-06-14
- ModerateDr. Reddy's Recalls Imatinib Mesylate Tablets for Dissolution Failures
FDA (Drugs) · 2021-03-03
- ModerateDr. Reddy's Recalls Rivastigmine Tartrate Capsules for Dissolution Failures
FDA (Drugs) · 2015-08-19
- HighTizanidine Tablets Recalled Nationwide for Failed Dissolution Specification
FDA (Drugs) · 2023-07-26